Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730–3735.
Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46: 678–684.
Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood 2018; 132: 1473–1477.
Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 2007; 92: 583–588.
Gaudio A, Morabito N, Catalano A, et al. Pathogenesis of thalassemia major-associated osteoporosis: A review with insights from clinical experience. J Clin Res Pediatr Endocrinol. 2019; 11: 110–117.
Datzmann T, Trautmann F, Tesch F, et al. Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. Leuk Res. 2018; 69: 81–86.
Karner CM, Lee S-Y, Long F. BMP induces osteoblast differentiation through both Smad4 and mTORC signaling. Mol Cell Biol. 2017; 37: .
Otaka N, Shibata R, Ohashi K, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. 2018; 123: 1326–1338.
Appleby SK, Chew-Harris JSC, Troughton RW, et al. Erythroferrone can diagnose acute decompensated heart failure in patients presenting with breathlessness. Medicine, 2018. http://www.semanticscholar.org/paper/Abstract-11094.
Spoto B, Kakkar R, Lo L, et al. Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: A two cohorts study. J Clin Med. 2019; 8: 523. .
Cuevas KR, Schobinger C, Gottardo E, et al. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoesis. Drug Test Anal. 2020; 12: 261–267.